Search

Your search keyword '"Facciabene, Andrea"' showing total 226 results
Start Over Author "Facciabene, Andrea"
226 results on '"Facciabene, Andrea"'

2. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2023
Full Text
View/download PDF

3. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

Author

Uribe-Herranz, Mireia, Beghi, Silvia, Ruella, Marco, Parvathaneni, Kalpana, Salaris, Silvano, Kostopoulos, Nektarios, George, Subin S., Pierini, Stefano, Krimitza, Elisavet, Costabile, Francesca, Ghilardi, Guido, Amelsberg, Kimberly V., Lee, Yong Gu, Pajarillo, Raymone, Markmann, Caroline, McGettigan-Croce, Bevin, Agarwal, Divyansh, Frey, Noelle, Lacey, Simon F., Scholler, John, Gabunia, Khatuna, Wu, Gary, Chong, Elise, Porter, David L., June, Carl H., Schuster, Stephen J., Bhoj, Vijay, and Facciabene, Andrea

Published
2023
Full Text
View/download PDF

5. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2022
Full Text
View/download PDF

7. Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

8. Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

9. Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

10. Data from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

11. Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

12. Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure Legends from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

14. Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

15. Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

17. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Author

Uribe-Herranz, Mireia, Rafail, Stavros, Beghi, Silvia, Gil-de-Gomez, Luis, Verginadis, Ioannis, Bittinger, Kyle, Pustylnikov, Sergey, Pierini, Stefano, Perales-Linares, Renzo, Blair, Ian A., Mesaros, Clementina A., Snyder, Nathaniel W., Bushman, Frederic, Koumenis, Constantinos, and Facciabene, Andrea

Subjects
Thermo Fisher Scientific Inc., Cancer treatment, Antigens, Microbiota (Symbiotic organisms), Tumors, Radiotherapy, Dendritic cells, Immune response, Antibacterial agents, Scientific equipment industry, T cells, Antibiotics, Cancer, Esters, Vancomycin, Diseases, Bacteria, Metabolites, Health care industry, University of Pennsylvania
Abstract

Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor- associated antigen (TAA) cross-priming with antitumor [CD8.sup.+] T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic [CD8.sup.+] T cells and on IFN-[gamma]. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications., Introduction Radiotherapy (RT) is a well-established antitumor treatment, with more than 50% of newly diagnosed cancer patients with solid tumors receiving RT at some point during their treatment, usually in [...]

Published
2020
Full Text
View/download PDF

20. Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, additional, Mohei, Hesham, additional, Beghi, Silvia, additional, Rivera, Osvaldo D., additional, Kostopoulos, Nektarios, additional, Giglio, Andrea, additional, George, Subin S., additional, Uribe-Herranz, Mireia, additional, Costabile, Francesca, additional, Pierini, Stefano, additional, Pustylnikov, Sergei, additional, Skoufos, Giorgos, additional, Barash, Yoseph, additional, Hatzigeorgiou, Artemis G., additional, Koumenis, Constantinos, additional, Maity, Amit, additional, Lotze, Michael T., additional, and Facciabene, Andrea, additional

Published
2023
Full Text
View/download PDF

22. Data from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Author

Monk, Bradley J., primary, Facciabene, Andrea, primary, Brady, William E., primary, Aghajanian, Carol A., primary, Fracasso, Paula M., primary, Walker, Joan L., primary, Lankes, Heather A., primary, Manjarrez, Kristi L., primary, Danet-Desnoyers, Gwenn-äel H., primary, Bell-McGuinn, Katherine M., primary, McCourt, Carolyn K., primary, Malykhin, Alexander, primary, Hershberg, Robert M., primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

23. Supplemental Tables from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Author

Monk, Bradley J., primary, Facciabene, Andrea, primary, Brady, William E., primary, Aghajanian, Carol A., primary, Fracasso, Paula M., primary, Walker, Joan L., primary, Lankes, Heather A., primary, Manjarrez, Kristi L., primary, Danet-Desnoyers, Gwenn-äel H., primary, Bell-McGuinn, Katherine M., primary, McCourt, Carolyn K., primary, Malykhin, Alexander, primary, Hershberg, Robert M., primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

24. Supplemental Figures from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Author

Monk, Bradley J., primary, Facciabene, Andrea, primary, Brady, William E., primary, Aghajanian, Carol A., primary, Fracasso, Paula M., primary, Walker, Joan L., primary, Lankes, Heather A., primary, Manjarrez, Kristi L., primary, Danet-Desnoyers, Gwenn-äel H., primary, Bell-McGuinn, Katherine M., primary, McCourt, Carolyn K., primary, Malykhin, Alexander, primary, Hershberg, Robert M., primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

25. Supplemental Figure Legends from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Author

Monk, Bradley J., primary, Facciabene, Andrea, primary, Brady, William E., primary, Aghajanian, Carol A., primary, Fracasso, Paula M., primary, Walker, Joan L., primary, Lankes, Heather A., primary, Manjarrez, Kristi L., primary, Danet-Desnoyers, Gwenn-äel H., primary, Bell-McGuinn, Katherine M., primary, McCourt, Carolyn K., primary, Malykhin, Alexander, primary, Hershberg, Robert M., primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

26. Supplemental Methods from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Author

Monk, Bradley J., primary, Facciabene, Andrea, primary, Brady, William E., primary, Aghajanian, Carol A., primary, Fracasso, Paula M., primary, Walker, Joan L., primary, Lankes, Heather A., primary, Manjarrez, Kristi L., primary, Danet-Desnoyers, Gwenn-äel H., primary, Bell-McGuinn, Katherine M., primary, McCourt, Carolyn K., primary, Malykhin, Alexander, primary, Hershberg, Robert M., primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

29. 572 Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects

Author

Facciabene, Andrea, primary, Uribe-Herranz, Mireia, additional, Beghi, Silvia, additional, Ruella, Marco, additional, Parvathaneni, Kalpana, additional, Ghilrardi, Guido, additional, Lee, Yung Gu, additional, Frey, Noelle, additional, Scholler, John, additional, Gabunia, Khatuna, additional, Specialist, Research, additional, Wu, Gary, additional, Chong, Elise, additional, Porter, David, additional, June, Carl, additional, Schuster, Stephen, additional, and Bhoj, Vijay, additional

Published
2022
Full Text
View/download PDF

30. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, primary, Dai, Anqi, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly V., additional, Devlin, Sean M., additional, Pajarillo, Raymone, additional, Slingerland, John B., additional, Beghi, Silvia, additional, Herrera, Pamela S., additional, Giardina, Paul, additional, Clurman, Annelie, additional, Dwomoh, Emmanuel, additional, Armijo, Gabriel, additional, Gomes, Antonio L. C., additional, Littmann, Eric R., additional, Schluter, Jonas, additional, Fontana, Emily, additional, Taur, Ying, additional, Park, Jae H., additional, Palomba, Maria Lia, additional, Halton, Elizabeth, additional, Ruiz, Josel, additional, Jain, Tania, additional, Pennisi, Martina, additional, Afuye, Aishat Olaide, additional, Perales, Miguel-Angel, additional, Freyer, Craig W., additional, Garfall, Alfred, additional, Gier, Shannon, additional, Nasta, Sunita, additional, Landsburg, Daniel, additional, Gerson, James, additional, Svoboda, Jakub, additional, Cross, Justin, additional, Chong, Elise A., additional, Giralt, Sergio, additional, Gill, Saar I., additional, Riviere, Isabelle, additional, Porter, David L., additional, Schuster, Stephen J., additional, Sadelain, Michel, additional, Frey, Noelle, additional, Brentjens, Renier J., additional, June, Carl H., additional, Pamer, Eric G., additional, Peled, Jonathan U., additional, Facciabene, Andrea, additional, van den Brink, Marcel R. M., additional, and Ruella, Marco, additional

Published
2022
Full Text
View/download PDF

34. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy

Author

Anstadt, Emily J, primary, Chu, Brian, additional, Yegya-Raman, Nikhil, additional, Han, Xiaoyan, additional, Doucette, Abigail, additional, Poirier, Kendra, additional, Mohiuddin, Jahan J, additional, Maity, Amit, additional, Facciabene, Andrea, additional, Amaravadi, Ravi K, additional, Karakousis, Giorgos C, additional, Cohen, Justine V, additional, Mitchell, Tara C, additional, Schuchter, Lynn M, additional, and Lukens, John N, additional

Published
2022
Full Text
View/download PDF

37. The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Author

Smith, Melody, primary, Dai, Anqi, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly, additional, Devlin, Sean M, additional, Pajarillo, Raymone, additional, Slingerland, John B, additional, Beghi, Silvia, additional, Herrera, Pamela S, additional, Giardina, Paul A, additional, Clurman, Annelie, additional, Dwomoh, Emmanuel A, additional, Armijo, Gabriel K, additional, Gomes, Antonio L.C., additional, Littmann, Eric R, additional, Schluter, Jonas, additional, Fontana, Emily, additional, Taur, Ying, additional, Park, Jae H, additional, Palomba, Maria Lia, additional, Halton, Elizabeth, additional, Ruiz, Josel D, additional, Jain, Tania, additional, Pennisi, Martina, additional, Afuye, Aishat Olaide, additional, Perales, Miguel-Angel, additional, Freyer, Craig W., additional, Garfall, Alfred L, additional, Gier, Shannon H, additional, Nasta, Sunita, additional, Landsburg, Daniel J, additional, Gerson, James N, additional, Svoboda, Jakub, additional, Cross, Justin, additional, Chong, Elise A, additional, Giralt, Sergio A, additional, Gill, Saar, additional, Rivière, Isabelle, additional, Porter, David L, additional, Schuster, Stephen J, additional, Sadelain, Michel, additional, Frey, Noelle V, additional, Brentjens, Renier J, additional, June, Carl H, additional, Pamer, Eric G, additional, Peled, Jonathan U, additional, Ruella, Marco, additional, van den Brink, Marcel, additional, and Facciabene, Andrea, additional

Published
2021
Full Text
View/download PDF

38. Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Author

Ruella, Marco, primary, Uribe-Herranz, Mireia, additional, Beghi, Silvia, additional, Parvathaneni, Kalpana, additional, Kostopoulos, Nektarios, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly, additional, Lee, Yong Gu Gu, additional, Pajarillo, Raymone, additional, Frey, Noelle V, additional, Lacey, Simon F, additional, Gabunia, Khatuna, additional, Scholler, John, additional, Chong, Elise A, additional, June, Carl H, additional, Porter, David L., additional, Schuster, Stephen J., additional, Bhoj, Vijay, additional, and Facciabene, Andrea, additional

Published
2021
Full Text
View/download PDF

39. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature

Author

Facciponte, John G., Ugel, Stefano, De Sanctis, Francesco, Li, Chunsheng, Wang, Liping, Nair, Gautham, Sehgal, Sandy, Raj, Arjun, Matthaiou, Efthymia, Coukos, George, and Facciabene, Andrea

Subjects
Tumor markers -- Research, Neovascularization -- Research, DNA vaccines -- Research, Immunotherapy -- Research, Tumors -- Blood-vessels, Health care industry
Abstract

Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is a protein found on tumor vasculature and in tumor stroma. Here, we tested whether TEM1 has potential as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with Teml cDNA fused to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). Tem1-TT vaccination elicited [CD8.sup.+] and/or [CD4.sup.+] T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization ofanimals with Tem1-TT prevented or delayed tumor formation in several murine tumor models. Therapeutic vaccination of tumor-bearing mice reduced tumor vascularity, increased infiltration of [CD3.sup.+] T cells into the tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited [CD8.sup.+] cytotoxic T cell responses against murine tumor-specific antigens. Effective Tem1-TT vaccination did not affect angiogenesis-dependent physiological processes, including wound healing and reproduction. Based on these data and the widespread expression of TEM1 on the vasculature of different tumor types, we conclude that targeting TEM1 has therapeutic potential in cancer immunotherapy., Introduction Angiogenesis, the growth of new blood vessels from preexisting vessels, is essential for many physiological processes, such as pregnancy, embryonic development, and wound healing (1). However, uncontrolled or defective [...]

Published
2014
Full Text
View/download PDF

40. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and [T.sub.reg] cells

Author

Facciabene, Andrea, Peng, Xiaohui, Hagemann, Ian S., Balint, Klara, Barchetti, Andrea, Wang, Li-Ping, Gimotty, Phyllis A., Gilks, C. Blake, Lal, Priti, Zhang, Lin, and Coukos, George

Subjects
Tumors -- Physiological aspects -- Health aspects -- Genetic aspects, Neovascularization -- Physiological aspects -- Health aspects, Hypoxia -- Health aspects -- Physiological aspects -- Genetic aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Although immune mechanisms can suppress tumour growth (1,2), tumours establish potent, overlapping mechanisms that mediate immune evasion (3-6). Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms (7-10). Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system (11). Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T ([T.sub.reg]) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth., Seventeen human ovarian cancer cell lines were incubated for 16 h in either hypoxic conditions (1.5% [O.sub.2]) or oxic conditions (21% [O.sub.2]). We used custom quantitative PCR (qPCR) arrays to [...]

Published
2011
Full Text
View/download PDF

42. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Author

Pierini, Stefano, primary, Mishra, Abhishek, additional, Perales-Linares, Renzo, additional, Uribe-Herranz, Mireia, additional, Beghi, Silvia, additional, Giglio, Andrea, additional, Pustylnikov, Sergei, additional, Costabile, Francesca, additional, Rafail, Stavros, additional, Amici, Augusto, additional, Facciponte, John G, additional, Koumenis, Costantinos, additional, and Facciabene, Andrea, additional

Published
2021
Full Text
View/download PDF

43. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

Author

Buckanovich, Ronald J, Facciabene, Andrea, Kim, Sarah, Benencia, Fabian, Sasaroli, Dimitra, Balint, Klara, Katsaros, Dionysios, O'Brien-Jenkins, Anne, Gimotty, Phyllis A, and Coukos, George

Subjects
Immunotherapy -- Research, Tumors -- Research, Tumors -- Genetic aspects, Ovarian cancer -- Research, Immune response -- Regulation, Immune response -- Research
Abstract

In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ET[sub.B]R) was associated with the absence of TILs and short patient survival time. The ET[sub.B]R inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ET[sub.B]R neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans., Author(s): Ronald J Buckanovich [1, 2, 7, 8]; Andrea Facciabene [1, 8]; Sarah Kim [1]; Fabian Benencia [1, 3]; Dimitra Sasaroli [1, 4]; Klara Balint [1]; Dionysios Katsaros [6]; Anne [...]

Published
2008
Full Text
View/download PDF

47. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes

Author

Adams, Sarah F, primary, Grimm, Alizée J, additional, Chiang, Cheryl L-L, additional, Mookerjee, Ananda, additional, Flies, Dallas, additional, Jean, Stephanie, additional, McCann, Georgia A, additional, Michaux, Justine, additional, Pak, HuiSong, additional, Huber, Florian, additional, Neal, Christopher, additional, Dangaj, Denarda, additional, Bassani-Sternberg, Michal, additional, Rusakiewicz, Sylvie, additional, Facciabene, Andrea, additional, Coukos, George, additional, Gimotty, Phyllis A, additional, and Kandalaft, Lana E, additional

Published
2020
Full Text
View/download PDF

48. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy

Author

Mohiuddin, Jahan J, primary, Chu, Brian, additional, Facciabene, Andrea, additional, Poirier, Kendra, additional, Wang, Xingmei, additional, Doucette, Abigail, additional, Zheng, Cathy, additional, Xu, Wei, additional, Anstadt, Emily J, additional, Amaravadi, Ravi K, additional, Karakousis, Giorgos C, additional, Mitchell, Tara C, additional, Huang, Alexander C, additional, Shabason, Jacob E, additional, Lin, Alexander, additional, Swisher-McClure, Samuel, additional, Maity, Amit, additional, Schuchter, Lynn M, additional, and Lukens, John N, additional

Published
2020
Full Text
View/download PDF

50. Association of antibiotic exposure with overall survival and colitis in patients with stage III and IV melanoma receiving immune checkpoint inhibitors.

Author

Chu, Brian, primary, Mohiuddin, Jahan J., additional, Facciabene, Andrea, additional, Wang, Xingmei, additional, Doucette, Abigail, additional, Zheng, Cathy, additional, Xu, Wei, additional, Amaravadi, Ravi K., additional, Karakousis, Giorgos C., additional, Mitchell, Tara C., additional, Maity, Amit, additional, Schuchter, Lynn Mara, additional, and Lukens, John Nicholas, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results